{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:49:51Z","timestamp":1786988991622,"version":"build-2736575974"},"reference-count":15,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","eu-focus.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Focus"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.euf.2022.08.002","type":"journal-article","created":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T19:18:55Z","timestamp":1660763935000},"page":"168-171","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["The Differential Risk of Mortality Among Users of Overactive Bladder Anticholinergic Medications and \u03b23 Agonists"],"prefix":"10.1016","volume":"9","author":[{"given":"Blayne","family":"Welk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euf.2022.08.002_b0005","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.eururo.2022.01.045","article-title":"European Association of Urology guidelines on the diagnosis and management of female non-neurogenic lower urinary tract symptoms. Part 1: diagnostics, overactive bladder, stress urinary incontinence, and mixed urinary incontinence","volume":"82","author":"Nambiar","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2022.08.002_b0010","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.eururo.2018.03.020","article-title":"Efficacy and tolerability of mirabegron compared with antimuscarinic monotherapy or combination therapies for overactive bladder: a systematic review and network meta-analysis","volume":"74","author":"Kelleher","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2022.08.002_b0015","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.eururo.2019.09.024","article-title":"Safety and efficacy of mirabegron: analysis of a large integrated clinical trial database of patients with overactive bladder receiving mirabegron, antimuscarinics, or placebo","volume":"77","author":"Chapple","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2022.08.002_b0020","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1038\/s41585-021-00504-x","article-title":"The cognitive effect of anticholinergics for patients with overactive bladder","volume":"18","author":"Welk","year":"2021","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.euf.2022.08.002_b0025","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1080\/14740338.2018.1453496","article-title":"Cardiovascular effects of antimuscarinic agents and beta3-adrenergic receptor agonist for the treatment of overactive bladder","volume":"17","author":"Rosa","year":"2018","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.euf.2022.08.002_b0030","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s00228-019-02795-x","article-title":"Association between anticholinergic drug burden and mortality in older people: a systematic review","volume":"76","author":"Ali","year":"2020","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.euf.2022.08.002_b0035","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1007\/s11606-020-05634-3","article-title":"Risk of mortality associated with non-selective antimuscarinic medications in older adults with dementia: a retrospective study","volume":"35","author":"Kachru","year":"2020","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.euf.2022.08.002_b0040","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1002\/phar.2121","article-title":"Variation in cardiovascular risk related to individual antimuscarinic drugs used to treat overactive bladder: a UK cohort study","volume":"38","author":"Arana","year":"2018","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.euf.2022.08.002_b0045","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1016\/j.jamda.2021.08.011","article-title":"Centrally acting anticholinergic drugs used for urinary conditions associated with worse outcomes in dementia","volume":"22","author":"Bishara","year":"2021","journal-title":"J Am Med Dir Assoc"},{"key":"10.1016\/j.euf.2022.08.002_b0050","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s00228-017-2359-3","article-title":"Comparison of cardiovascular events among treatments for overactive bladder: a Danish nationwide cohort study","volume":"74","author":"Margulis","year":"2018","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.euf.2022.08.002_b0055","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1007\/s40264-021-01095-7","article-title":"Cardiovascular risk in users of mirabegron compared with users of antimuscarinic treatments for overactive bladder: findings from a non-interventional, multinational, cohort study","volume":"44","author":"Hoffman","year":"2021","journal-title":"Drug Saf"},{"key":"10.1016\/j.euf.2022.08.002_b0060","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1001\/jamainternmed.2019.2011","article-title":"Association of mirabegron with the risk of arrhythmia in adult patients 66 years or older\u2014a population-based cohort study","volume":"179","author":"Tadrous","year":"2019","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.euf.2022.08.002_b0065","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1002\/nau.24827","article-title":"The risk of delirium and falls or fractures with the use of overactive bladder anticholinergic medications","volume":"41","author":"Welk","year":"2022","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.euf.2022.08.002_b0070","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1177\/1074248408325404","article-title":"Differential pharmacological effects of antimuscarinic drugs on heart rate: a randomized, placebo-controlled, double-blind, crossover study with tolterodine and darifenacin in healthy participants \u226550 years","volume":"13","author":"Olshansky","year":"2008","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"10.1016\/j.euf.2022.08.002_b0075","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1007\/s40266-019-00694-5","article-title":"The relationship between anticholinergic exposure and falls, fractures, and mortality in patients with overactive bladder","volume":"36","author":"Suehs","year":"2019","journal-title":"Drugs Aging"}],"container-title":["European Urology Focus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456922001717?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456922001717?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T06:54:15Z","timestamp":1762498455000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405456922001717"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S2405456922001717"],"URL":"https:\/\/doi.org\/10.1016\/j.euf.2022.08.002","relation":{},"ISSN":["2405-4569"],"issn-type":[{"value":"2405-4569","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Differential Risk of Mortality Among Users of Overactive Bladder Anticholinergic Medications and \u03b23 Agonists","name":"articletitle","label":"Article Title"},{"value":"European Urology Focus","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euf.2022.08.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}